These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32145255)

  • 1. Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation.
    Gabr A; Ranganathan S; Mouli SK; Riaz A; Gates VL; Kulik L; Ganger D; Maddur H; Moore C; Hohlastos E; Katariya N; Caicedo JC; Kalyan A; Lewandowski RJ; Salem R
    J Hepatol; 2020 Jun; 72(6):1151-1158. PubMed ID: 32145255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Dosimetric Implications of Calculating Lung Shunt Fraction for Hepatic
    Struycken L; Patel M; Kuo P; Hennemeyer C; Woodhead G; McGregor H
    AJR Am J Roentgenol; 2022 Apr; 218(4):728-737. PubMed ID: 34704460
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort.
    Das A; Riaz A; Gabr A; Ali R; Mora R; Al Asadi A; Mouli S; Lewandowski RJ; Salem R
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):807-815. PubMed ID: 31502015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting.
    Gaba RC; Zivin SP; Dikopf MS; Parvinian A; Casadaban LC; Lu Y; Bui JT
    Radiology; 2014 May; 271(2):602-12. PubMed ID: 24533871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeat Evaluation of Lung Shunt Fraction is Unnecessary: A Retrospective Observational Study of Successive Lung Shunt Fractions from Variable Arterial Distributions in Patients Undergoing Radioembolization of Primary and Secondary Liver Tumors.
    Bulman JC; Zurkiya O; Wu V; Wehrenberg-Klee E; Palmer E; Chow D; Brook A; Ganguli S
    J Vasc Interv Radiol; 2021 Mar; 32(3):412-418. PubMed ID: 33341340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-Session Ablative Transarterial Radioembolization for Patients with Hepatocellular Carcinoma to Streamline Care: An Initial Experience.
    Berman ZT; Pianka K; Qaseem Y; Redmond J; Minocha J
    Cardiovasc Intervent Radiol; 2024 Sep; 47(9):1239-1245. PubMed ID: 38977445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival.
    Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS
    Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
    Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
    Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indicators of Lung Shunt Fraction Determined by Technetium-99 m Macroaggregated Albumin in Patients with Hepatocellular Carcinoma.
    Kallini JR; Gabr A; Hickey R; Kulik L; Desai K; Yang Y; Gates VL; Riaz A; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1213-1222. PubMed ID: 28280976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung Shunt Reduction for Yttrium-90 Radioembolization: Chemoembolization
    Kim HC; Choi JW; Lee M; Kim YJ; Paeng JC; Chung JW
    In Vivo; 2021; 35(4):2305-2312. PubMed ID: 34182510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?
    Elsayed M; Cheng B; Xing M; Sethi I; Brandon D; Schuster DM; Bercu Z; Galt J; Barron B; Kokabi N
    Cardiovasc Intervent Radiol; 2021 Feb; 44(2):254-260. PubMed ID: 33000319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
    J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization.
    Puranik AD; Rangarajan V; Gosavi A; Shetty N; Gala K; Kulkarni S; Mohite A; Patkar S; Goel M; Shrikhande SV; Ramaswamy A; Ostwal V; Purandare NC; Agrawal A; Shah S
    Nucl Med Commun; 2021 Mar; 42(3):337-344. PubMed ID: 33306631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of
    Allred JD; Niedbala J; Mikell JK; Owen D; Frey KA; Dewaraja YK
    EJNMMI Res; 2018 Jun; 8(1):50. PubMed ID: 29904808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
    Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
    Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma.
    Li Q; Wang X; Li D; Liu Y; Liu K; Liang J; Sun J; Jiang Q; Li J; Liu Z; Gong J; Xiang L; Jia Z; Chen Z; Cao M; Jiang Y
    J Vis Exp; 2024 May; (207):. PubMed ID: 38856215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging Predictors of Elevated Lung Shunt Fraction in Patients Being Considered for Yttrium-90 Radioembolization.
    Olorunsola OG; Kohi MP; Behr SC; Kolli PK; Taylor AG; Tong RT; LaBerge JM; Kerlan RK; Fidelman N
    J Vasc Interv Radiol; 2015 Oct; 26(10):1472-8. PubMed ID: 26296737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.